Eyenovia Names John Gandolfo as Chief Financial Officer
11 January 2018 - - US-based ophthalmic pharmaceutical company Eyenovia Inc. has appointed John Gandolfo as chief financial officer effective December 18, 2017, the company said.
Gandolfo has more than 30 years of experience in executive and senior management positions with high growth public and private companies, primarily in the medical devices and life sciences sectors.
He has assisted in raising approximately USD 500m in capital through public market transactions and private investors, venture capitalists and debt transactions.
Prior to joining Eyenovia, Gandolfo spent more than seven years at Xtant Medical Holdings, Inc., where he served as CFO. He has also served as the CFO at Progenitor Cell Therapy LLC, Power Medical Interventions, Inc., and Bioject, Inc.
Gandolfo is a graduate of Rutgers University and started his professional career at Price Waterhouse.
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics.
The company's pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.